|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 401 C St NE |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20002 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Minneapolis |
State | MN |
Zip Code | 55415 |
Country | USA |
|
5. Senate ID# 300856-12
|
||||||||
|
6. House ID# 377350000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Derek C. Brandt |
Date | 10/21/2019 4:49:17 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 73: End Taxpayer Subsidies for Drug Ads Act; all provisions.
S. 1384: Prescription Drug Rebate Reform Act of 2019; all provisions.
S. 1391 / H.R. 2296: FAIR Accountability and Innovative Research Drug Pricing Act; all provisions.
S.1622, Stopping Overdoses of Fentanyl Analogues Act; all provisions.
S.2546 / H.R. 2279: Safe Step Act; all provisions.
H.R. 2471: Healthcare Extension and Accessibility for Developmentally Disabled and Underserved Population Act of 2019; all provisions.
H.R. 3030: Patient-Centered Outcomes Research Extension Act of 2019; all provisions.
H.R. 3439: Protecting Access to Information for Effective and Necessary Treatment (PATIENTS) Act of 2019; all provisions.
HR 3502, Protecting People from Surprise Medical Bills Act; all provisions.
Authorizing and funding the pediatric loan repayment program.
Supporting policies to address prescription drug costs, including improving drug pricing transparency and eliminating or reducing direct-to-consumer advertising.
Funding for the National Neurological Conditions Surveillance System and opposing certain expansions to this program.
Research into firearm morbidity and mortality prevention at CDC, fetal tissue research, and the NIH including the BRAIN Initiative.
Funding for Congressionally Directed Medical Research Programs at the DoD.
Raising budget caps to avoid sequestration.
Policy to address surprise medical billing.
Promoting interoperability in electronic health records.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
|
Matthew |
Kerschner |
|
|
|
Natalie |
Pontzer |
|
|
|
Michael |
Lisowski |
|
Senior Legislative Assistant, Rep. Joe Heck. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 2543: Prescription Drug Pricing Reduction Act; sections 102, 107, 110, 121, 128, 141.
HR 3: Lower Drug Costs Now Act of 2019; all provisions.
H.R. 3107: Improving Seniors' Timely Access to Care Act of 2019; all provisions.
Excluding non-invasive ventilators from the 2021 competitive bidding program
CMS proposed rule altering Evaluation and Management and long-term electroencephalogram (EEG) billing codes.
Supporting policies to address prescription drug costs, including supporting direct negotiation in Medicare, improving drug pricing transparency, extending negotiated Rx discounts to be passed through to patients cost-sharing requirements, and capping beneficiary out-of-pocket costs in Medicare Part D.
Issues associated with Qualified Clinical Data Registry implementation, measures, and interoperability.
Improvements to the Medicare Access and CHIP Reauthorization Act of 2015.
Medicare coverage of oxygen therapy for cluster headaches.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
|
Matthew |
Kerschner |
|
|
|
Natalie |
Pontzer |
|
|
|
Michael |
Lisowski |
|
Senior Legislative Assistant, Rep. Joe Heck. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Strengthening the VA Centers of Excellence
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 88; Section 505: Repeal of Unrelated Business Income Tax on Qualified Transportation Fringe Benefits
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |